There is a sentence that recurs whenever a serious researcher is asked about the longevity supplement boom, and it surfaced again this month in NPR’s reporting on NAD+ infusions. Christopher Martens, who runs cognitive-aging research at the University of Delaware and studies the molecule directly, put it plainly: the cart may be well ahead of the horse. It is worth pausing on, because the man saying it is not a sceptic of the science. He is one of the people doing it.
The boom is real and the numbers are large. NAD+ — sold as pills, injectables and IV drips — has swept through the wellness world on the back of celebrity endorsement and a genuinely attractive hypothesis: levels of the molecule decline with age, that decline may contribute to age-related disease, so topping it up should help. Brain supplements tell a parallel story. Americans spend billions a year on bottles promising sharper minds, and as The Washington Post noted this month, only one such supplement has been shown in clinical trials to slow cognitive aging at all — by roughly two years.
The gap between hypothesis and evidence is where VeyrZest readers should focus, because it is wide and specific. The NAD+ case is instructive. In rodents, the molecule looks close to miraculous — better mitochondrial function, more strength, less inflammation. In humans, the picture thins dramatically. As Brigham and Women’s researcher Shalender Bhasin frames it, the idea is very attractive, but the health benefits of boosting NAD+ remain unestablished in large human studies. There is even a mechanical problem: NAD+ has no easy route into the cell from the bloodstream, which means an expensive infusion may be, in one researcher’s word, inefficient — the molecule arrives but cannot get where it is needed.
None of this means the science is empty. It means the science is early, and early science and a mature consumer market are a dangerous pairing. The market does not wait for trials. It runs on plausibility, testimonials and the particular anxiety of the moment — the belief that the self is something to be tuned and upgraded, its limits negotiable through the right regimen. Cognitive health, once the domain of illness, has become another optimisation frontier. And optimisation culture has a structural flaw: it cannot tell the difference between a molecule that works and a molecule that merely has a good story, because both produce the same thing — a confident purchase.
So how should a serious person navigate this? Not with blanket cynicism; some of the underlying research is being done by excellent scientists, and dismissing the entire space as quackery is its own error. The discipline is more useful than the verdict. Ask what kind of evidence supports a claim — rodent or human, anecdote or trial, mechanism or outcome. Ask whether a delivery method even makes biological sense before paying for it. Treat ‘real people report it helps them’ as a signal worth following up, not a proof. And notice when a product’s marketing budget is doing work its trial data has not yet earned.
The longevity field is, encouragingly, maturing in exactly this direction — moving from scattered proof-of-concept studies toward the kind of standardised clinical evaluation that defines a real biomedical discipline. The consumer market has not made that turn. It is still selling the 2015 version of the story while the labs have moved on.
For those who take time seriously, the longevity supplement aisle is a test of temperament. The reward goes not to the earliest adopter but to the most patient reader of evidence. The horse is real. It is worth waiting for it to get in front of the cart.
